Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

NCT06667973 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
FLT3 Gene Mutation
Adult AML
Diagnosis

Interventions

DRUG: Gilteritinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto